Radiopharmaceutical Trial Supply: When Your Drug Expires on the Way to the Clinic

Every supply chain fights expiry. Radiopharmaceutical supply chains fight physics. A lutetium-177 dose loses about 10% of its activity per day. Fluorine-18 has a half-life under two hours. Actinium-225 sits in between but comes with a raw material shortage that makes every dose precious. You cannot build safety stock of a product that decays while it sits on the shelf.

Radioligand therapies are one of the fastest growing areas in oncology, and the trial pipeline has grown with them. Sponsors coming from small molecules or biologics tend to underestimate how different this is. Almost every habit of conventional clinical supply (buffer stock, depot networks, generous resupply windows) stops working.

Every dose is made for a patient and a day

Most radiopharmaceutical trials run as make-to-order. A patient is scheduled, a dose is manufactured for that patient's treatment date, it is released, and it travels to the site to arrive within a calibration window. If the patient cancels the morning of dosing, the dose is usually lost. If the flight is delayed, the dose may arrive with too little activity to use.

That changes the planning unit. You are not forecasting kits per site per month. You are booking manufacturing slots, transport, and site treatment rooms as a linked calendar, and protecting that calendar from small disruptions that would be trivial anywhere else.

Manufacturing slots are the real constraint

Production capacity for radiopharmaceuticals is limited, and so is isotope supply. Reactors that produce medical isotopes go down for maintenance, and an unplanned outage can cut supply across the industry for weeks. Questions to settle early:

• How many production runs per week, and on which days? Treatment schedules at sites have to line up with these.
• Is there a second manufacturing site or isotope source? A single point of failure here halts dosing for every patient.
• What is the release turnaround? QC tests and release for short half-life products have to finish within hours, and some tests finish after the product has shipped, which needs a clear agreement with regulators.
• How are slots shared with other trials or commercial product? If the same facility supplies a marketed product, your trial will not always win.

Logistics measured in hours

Radioactive shipments travel as dangerous goods under IATA and national transport rules. Not every airline accepts them, not every courier is certified, and some routes forbid them entirely. The result is a smaller set of usable lanes, so build them deliberately:

• Qualify primary and backup routes for every site, with real transit times measured in hours.
• Agree on a cut-off time after which a dose will not arrive with enough activity, and an escalation path when a shipment approaches it.
• Check customs. A two-hour customs hold that would not matter for a tablet can kill a dose here. Pre-clearance arrangements are worth the effort for cross-border lanes.

Sites need more than a pharmacy

A radiopharmaceutical site needs a radioactive materials license, a nuclear medicine department, trained staff, shielded storage, and a plan for waste and patient release. Patients may need to stay in shielded rooms or follow restrictions after dosing. All of this narrows site selection, so the supply team should weigh in before sites are chosen. A site four hours from the nearest airport receiving dangerous goods may be clinically excellent and logistically impossible.

Scheduling is the supply plan

In conventional trials, IRT allocates from stock that already exists. In radiopharmaceutical trials, the system often has to order a dose for a specific patient and date, then track it through manufacture, release, and transport. Some sponsors use an orchestration platform on top of IRT for this. Either way, the scheduling workflow should be tested end to end before first patient, including cancellations, reschedules, and failed doses.

Plan for waste honestly. Some doses will be lost to cancellations and delays. Budget for that loss rate instead of pretending it will be zero, and track it as a key metric so you can see when a site or lane is drifting.

Blinding and comparators

Blinding a radioactive product is hard, and many radioligand trials are open label for that reason. When there is a comparator arm, it is often standard of care sourced locally or centrally, with its own conventional supply chain running beside the make-to-order one. Two supply models in one trial means two sets of risks, so give each one an owner.